Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
30 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/30/2920974/0/en/Yamo-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Study-of-L1-79-for-the-Treatment-of-the-Core-Symptoms-of-Autism.html
20 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/11/20/2783221/0/en/Yamo-Pharmaceuticals-Enrolls-Final-Patient-in-Phase-2-Study-Evaluating-L1-79-to-Treat-the-Core-Symptoms-of-Autism-Spectrum-Disorder.html
28 Jan 2022
// CLINICALTRIALSARENA
https://www.clinicaltrialsarena.com/news/yamo-autism-therapytrial/
27 Jan 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/01/27/2374277/0/en/Yamo-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html
Details:
L1-79 is a tyrosine hydroxylase inhibitor expected to modulate the catecholaminergic pathways, and thereby improve the core autism spectrum disorder symptoms.
Lead Product(s): Methyltyrosine
Therapeutic Area: Neurology Brand Name: L1-79
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2024
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yamo Pharmaceuticals Reports Positive Data from Phase 2 Study of L1-79 in Autism
Details : L1-79 is a tyrosine hydroxylase inhibitor expected to modulate the catecholaminergic pathways, and thereby improve the core autism spectrum disorder symptoms.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 30, 2024
Details:
L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).
Lead Product(s): Methyltyrosine
Therapeutic Area: Neurology Brand Name: L1-79
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2023
Details:
As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.
Lead Product(s): Methyltyrosine
Therapeutic Area: Neurology Brand Name: L1-79
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: The Autism Impact Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 10, 2021
Lead Product(s) : Methyltyrosine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : The Autism Impact Fund
Deal Size : Undisclosed
Deal Type : Financing
Details : As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.
Brand Name : L1-79
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 10, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?